Phase 3a trial in Japan/Taiwan shows cagrilintide-semaglutide combination delivers superior weight loss (18.4%) versus semaglutide alone (11.9%) in adults with overweight/obesity ± type 2 diabetes, with comparable safety profiles dominated by manageable gastrointestinal side effects.